Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at ... (NNRTI) for the potential treatment of HI...)

Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC

Date:9/19/2007

NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 possesses several attractive properties. These include: potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.

About Ardea Biosciences, Inc.

Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, scheduled to enter Phase 1 clinical trials in the second half of 2007, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of initiating a Phase 2 study of RDEA806 in HIV-infected patients and initiating clinical studies on three additional comp
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Post Your Comments:

(Date:12/14/2009)... THE WOODLANDS, Texas, Dec. 14 /PRNewswire/ ... investigators affiliated with US Oncology ... were presented orally at the ... , held Dec. 9-13 at the ... in San Antonio, Texas . ...

(Date:12/14/2009)... -- Perry Baromedical, international leader in Hyperbaric Chamber ... the Sigma Elite, with extended patient data capture ... is available on each monoplace chamber model currently ... Pending. ,, The Sigma Elite New "Smart Hyperbaric ... System for Each Dive Electronic (EMR) ...

(Date:12/14/2009)... CHICAGO, Dec. 14 Sword Diagnostics, Inc. ... Patent Office (USPTO) has issued patent number ... Biological Organisms using Raman Scattering" to the company. ... on improved sensitivity. ,, "The issuance of ... move forward with our continued development and commercialization," ...

[0] US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium [0] Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability [0] U.S. Patent Office Issues Sword Diagnostics Patent for Highly Sensitive Immunodetection Technology

... WIRE)--Apr 25, 2007 - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today ... an intrinsic cell survival,pathway impacts the anticancer activity ... NF-kB, enhanced the tumor killing effects of,INGN 241 ... human tumors.,Researchers at Introgen and The University of ...

... 2007 - OSI,Pharmaceuticals, Inc. (Nasdaq: OSIP) announced ... of Clinical Oncology show that,adding Tarceva(R) (erlotinib) ... as first-line,therapy to patients with advanced pancreatic ... National Cancer Institute of Canada (NCIC),formed the ...

Other Medicine Technology:Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2 Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3 OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 2 OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 3 OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 4

Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer

(Date:12/14/2009)... nursing facilities (SNFs) in Ohio are making major changes ... a 92 percent increase in the state-imposed Medicaid bed ... bed per day, scheduled for December 15. The ... additional $17,520 to the state each month, or $210,240 ... ,, Nearly 96 percent of skilled nursing facilities responding ...

(Date:12/14/2009)... to Stemming Tide of Tens of Thousands of ... Dec. 14 Legislation approved by Congress ... be crucial in helping to reduce tens of ... year in the United States, the National ... The provision was included in the FY 2010 ...

(Date:12/14/2009)... The Hemophilia Federation of America (HFA) ... involving the Teamsters Local 929 and the American ... blood system depends on skilled workers to provide ... distilled into products such as clotting factor for ... ,, The Division of Blood Services at ...

(Date:12/14/2009)... When Kurth Krause, an aerospace engineer,for NASA, was ... the moon, he,was confident that technology and science ... there was one thing that science couldn,t solve.,His ... though dialysis machines,would keep her alive for awhile, ... wife is 69 and is starting dialysis next ...

(Date:12/14/2009)... be linked to scans performed in 2007 , , MONDAY, ... exposing patients to far more radiation than previously thought and ... a year, two new studies claim. , Based on the ... Archives of Internal Medicine , the study authors, joined by ... on clinicians to limit radiation exposure to patients. , "CT ...

Breaking Medicine News(10 mins):Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2 Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3 Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2 Health News:HFA Voices Blood Safety Concerns 2 Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2 Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3 Health News:Studies Quantify Cancer Risks From CT Scans 2 Health News:Studies Quantify Cancer Risks From CT Scans 3 Health News:Studies Quantify Cancer Risks From CT Scans 4

[1] Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts [0] NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange [0] HFA Voices Blood Safety Concerns [0] 69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger [0] Studies Quantify Cancer Risks From CT Scans

... Technology , , SOMERVILLE, ... device company, today announced the launch of the PROCEED ... family of hernia products. PVP Device is the first ... and exclusive, absorbable deployment technology. It is indicated for ...

... , , SEATTLE, Dec. 16 ... Hutchinson Cancer Research Center,s "Get Screened" video contest - a creative ... screening. All entries are due by Jan. 15, 2009. , ... Hutchinson Center,s ongoing awareness campaign - "Your colon. Your life. ...

... 16 The ASCII Group, Inc. (ASCII), the nation,s ... has announced a partnership with Association Health Programs (AHP) ... the cost of health insurance. The program will ... a comprehensive health insurance program for individuals, families, groups, ...

... Programs and Next Year,s Services , , ... Chicago is facing a grave financial shortfall which will severely ... of donations increases this Christmas season according to its commanding ... , "The economic downturn has attacked us on ...

... Improve Ease of Use and Speed , , BOSTON, ... improved version of its producer website ( www.jhltc.com ) to make it easier for ... tools online. , , Enhancements to the site include: ... Faster speed of processing , ...

... deadly,bacteria in lungs , , TUESDAY, Dec. 16 (HealthDay News) ... in the lungs of cystic fibrosis patients are signaling ... The pigments may enable infectious Pseudomonas aeruginosa ... Massachusetts Institute of Technology (MIT) study. , The ...

Other Medicine News:Health News:ETHICON Launches the Latest Innovation in Hernia Repair Platform; PROCEED(TM) Ventral Patch (PVP(TM) Device) 2 Health News:A Month Left to Enter the 'Get Screened' Video Contest for a Chance to Win Up to $2,500 2 Health News:The ASCII Group Partners with Association Health Programs to Counter Rising Health Insurance Costs 2 Health News:Salvation Army Services Threatened by Pace of Donations 2 Health News:John Hancock LTC Enhances Producer Website 2 Health News:John Hancock LTC Enhances Producer Website 3 Health News:Scientists Spot Key to Cystic Fibrosis Infections 2

ETHICON Launches the Latest Innovation in Hernia Repair Platform; PROCEED(TM) Ventral Patch (PVP(TM) Device)A Month Left to Enter the 'Get Screened' Video Contest for a Chance to Win Up to $2,500 The ASCII Group Partners with Association Health Programs to Counter Rising Health Insurance Costs Salvation Army Services Threatened by Pace of Donations John Hancock LTC Enhances Producer Website Scientists Spot Key to Cystic Fibrosis Infections

CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...

Selute Picotip Atrial-J steroid eluting passive fixation lead...

Unipolar temporary atrial pacing lead is smaller and thinner than Medtronics standard temporary pacing leads. It is well suited for thin, delicate, atrial tissue....

VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....

Medicine Products:

CapSure SP Novus Selute Picotip Atrial J Atrial 6492 VascoTip P 9/60 PU S

Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at ...(NNRTI) for the potential treatment of HI...),Health